Delving into the Latest Updates on Zambon GmbH with Synapse

Non-interventional study X-TRASafety and efficacy of safinamide (Xadago®) as add-on therapy to levodopa in mid- to late-stage Parkinson’s disease patients – a non-interventional observational study in daily practice of German neurologists - X-TRA

开始日期2015-09-03

申办/合作机构

Zambon GmbH

100 项与 Zambon GmbH 相关的临床结果

登录后查看更多信息

0 项与 Zambon GmbH 相关的专利（医药）

登录后查看更多信息

3

项与 Zambon GmbH 相关的文献（医药）

2023-12-02·Current Medical Research and Opinion

Real world data of a German Parkinson’s disease population: effectiveness and safety of safinamide in routine clinical practice

Article

作者: Jost, Wolfgang H ; Lück, Jennifer C ; Lopes, Olga I Fonseca da Cruz ; Gluth, Ivonne

BACKGROUNDParkinson's Disease (PD) is a common progressive neurodegenerative disorder that leads to an imbalance of various neurotransmitters and affects cognitive, motor and non-motor function. Safinamide inhibits monoamine oxidase B in a highly selective and reversible manner and beyond that has anti-glutamatergic properties, with positive effects on motor and non-motor symptoms. The aim of the study was to obtain data about the effectiveness and tolerability of safinamide under routine clinical practice conditions in unselected patients with Parkinson's disease (PD).METHODSA post-hoc analysis of the German cohort of the European SYNAPSES study (a non-interventional cohort study). Patients were treated with safinamide as an add-on to levodopa and followed-up for 12 months. Analyses were done in the total cohort and in clinically relevant subgroups (patients older than 75 years; with relevant comorbidities; with psychiatric conditions).RESULTS181 PD patients were eligible for analysis. Motor symptoms included bradykinesia (76.8%), rigidity (77.3%), tremor (58.6%), and postural instability (27.1%). Non-motor symptoms were reported in 161 patients (89.0%), mainly psychiatric symptoms (43.1%), sleep disorders (35.9%), fatigue (30.9%), and pain (27.6%). 28.7% of patients were aged 75 years or older, 84.5% had relevant comorbidities, and 38.1% had psychiatric conditions. During treatment, the rate of motor complications decreased from 100.0% to 71.1%. UPDRS scores improved under safinamide, with a clinically important effect in 50% in the total score and 45% in the motor score. The positive effect on motor complications occurred already at the 4-month visit and was maintained over 12 months. At least one adverse event (AE)/adverse drug reaction (ADR) was reported by 62.4%/25.4% of patients, AEs were generally mild or moderate, and completely resolved. Only 5 (1.5%) AEs had a definite relationship to safinamide.CONCLUSIONSThe benefit-risk profile of safinamide was favourable and consistent with the total cohort of the SYNAPSES study. In the subgroups, findings were congruent with the total population, which allows the clinical utilisation of safinamide also in more vulnerable patient groups.

2018-10-01·Fortschritte der Neurologie · Psychiatrie4区 · 医学

Wirksamkeit und Sicherheit von Safinamid als Zusatztherapie zu Levodopa bei Parkinson-Patienten: eine nicht-interventionelle Beobachtungsstudie

4区 · 医学

Article

作者: Bosse, Dietrich ; Kupsch, Andreas ; Mengs, Jörg ; Jost, Wolfgang H. ; Delf, Martin

Aktuelle Neurologie

Medikamentöse Therapie des Parkinson-Syndroms: Selbsteinschätzung der Parkinson-Patienten in einer Querschnittserhebung

作者: Engemann, K. ; Jost, W.

100 项与 Zambon GmbH 相关的药物交易

登录后查看更多信息

100 项与 Zambon GmbH 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

1

13

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

磷霉素氨丁三醇 ( EPT )	泌尿道感染更多	批准上市
ZP-051(Zambon GmbH)	慢性阻塞性肺疾病更多	临床阶段不明
SIM-6080 ( VDCCs )	高脂血症更多	终止
Asobamast ( LTRs )	哮喘更多	终止
GW-796406 ( ACE x CD10 )	高血压更多	终止